Last reviewed · How we verify
TRx0237
TRx0237 is a tau aggregation inhibitor.
TRx0237 is a tau aggregation inhibitor. Used for Alzheimer's disease.
At a glance
| Generic name | TRx0237 |
|---|---|
| Sponsor | TauRx Therapeutics Ltd |
| Drug class | tau aggregation inhibitor |
| Target | tau protein |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to tau protein and preventing its aggregation, which is a hallmark of neurodegenerative diseases such as Alzheimer's disease. This mechanism is thought to slow disease progression and potentially halt the progression of cognitive decline.
Approved indications
- Alzheimer's disease
Common side effects
- Headache
- Dizziness
- Nausea
Key clinical trials
- Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment (PHASE3)
- TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease
- Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) (PHASE3)
- Clinical Application of Methylene Blue for Treatment of Covid-19 Patients (PHASE1)
- Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) (PHASE3)
- Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease (PHASE3)
- Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease (PHASE3)
- Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRx0237 CI brief — competitive landscape report
- TRx0237 updates RSS · CI watch RSS
- TauRx Therapeutics Ltd portfolio CI